After 1 year of anti-obesity treatments, SPARC levels decreased significantly throughout the cohort, LEI + topiramate, LEI + liraglutide, and LEI + bariatric/metabolic surgery, where they were groups that showed significant weight loss. The gene discussed is SPARC; the disease is Obesity.